Project Grant R01DA064086
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $432,754 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop dual enkephalinase inhibitor-based therapies for treating nociceptive sensitization and opioid withdrawal symptoms in offspring with prenatal fentanyl exposure. The research addresses a documented public health crisis: from 2017 to 2020, opioid use disorder diagnoses in pregnant women increased...
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $647,142 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct two randomized, double-blind, placebo-controlled inpatient studies examining how cannabis affects opioid self-administration in individuals with moderate-to-severe opioid use disorder and opioid physical dependence. Study 1 will determine how repeated inhaled cannabis exposure (active cannabis at...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $701,569 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the use and effectiveness of medications for opioid use disorder in older adults with multimorbidity. The award funds quantitative studies of Medicare and Veterans Health Administration enrollees with diagnosed opioid use disorder and a qualitative study of older adults with opioid use disorder and...
- The National Institute on Drug Abuse awarded Drexel University $832,132 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate novel circuit mechanisms underlying opioid-induced dopamine elevations in the nucleus accumbens, operating beyond the canonical midbrain dopamine neuron pathway. The research explores how oxycodone enhances dopamine signals through local circuits in the nucleus accumbens, specifically examining the role of GABA and cholinergic...
- The National Institute on Drug Abuse awarded Johns Hopkins University $198,164 on October 17, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research examining barriers to medications for opioid use disorder (MOUD) treatment for individuals transitioning from correctional facilities to community settings. The research employs a complex systems approach combining quantitative and qualitative methods. Specific aims include examining the structure and function...
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $422,921 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support the STAR (Support Towards Addiction Recovery) Project, an R61 phase award responding to RFA-DA-26-024. The award funds adaptation and feasibility testing of an innovative dyadic intervention designed to improve recovery capital and increase support for loved ones of individuals in recovery from substance...
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $2.175 million on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled clinical trial evaluating non-abstinence treatment outcomes for methamphetamine use disorder. The trial will enroll 200 treatment-seeking individuals with methamphetamine use disorder and randomly assign them to two groups: one receiving financial incentives...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $198,164 on September 25, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research examining delta opioid receptor regulation of parvalbumin interneuron transmission and oxycodone-related behavior. The project investigates how delta opioid receptor signaling in parvalbumin-expressing GABAergic interneurons within the prefrontal cortex contributes to opioid use disorder symptoms,...
- The National Institute on Drug Abuse awarded New York University $103,607 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct dissertation research on polysubstance use patterns and their associations with methadone maintenance treatment receipt and discontinuation among people who use drugs in New York State. The research uses a mixed-methods approach guided by the Social Ecological Model to identify latent polysubstance use patterns through urine...
- The National Institute on Drug Abuse awarded Vanderbilt University Medical Center $825,492 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a comparative analysis of buprenorphine dosing and clinical outcomes across pregnant and non-pregnant populations with opioid use disorder. The research addresses the gap between clinical evidence and practice in medication-assisted treatment during pregnancy. The study assesses national and state-level...
The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $548,992 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop county-level prevalence estimates for opioid use disorder using capture-recapture and Bayesian modeling techniques. The research generates opioid use disorder prevalence estimates by county and year using capture-recapture analysis linked to data from multiple participating states, comparing results against Bayesian benchmark multiplier and Bayesian integrated abundance models. A second aim conducts Bayesian spatial regression analyses to associate the prevalence estimates with publicly available county-level covariates, ultimately enabling projection of opioid use disorder prevalence to counties with missing data. A third aim focuses on recruiting additional states, primarily those participating in the Centers for Disease Control and Prevention's Overdose to Action Project. The project will produce a transferable framework for estimating hidden and vulnerable populations across varying state resource contexts and will inform targeted public health responses and resource allocation. Performance occurs in Lexington, Kentucky, with work extending through June 30, 2031. The assistance type is a Project Grant, supporting basic and translational research in substance use as defined by the NIDA program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $549.0k | 8/31/26 |